BPC-157
Tissue Repair & Angiogenic Signaling
What is BPC-157?
BPC-157 ("Body Protection Compound-157") is a synthetic pentadecapeptide — a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of roughly 1,419.55 Da. Its sequence is derived from a fragment of a protein identified in human gastric juice, and it does not occur in this stabilized form in nature. Within preclinical regenerative science it is one of the most frequently investigated peptides, largely because it appears stable in aqueous and acidic environments where many peptides degrade rapidly.
The proposed mechanisms of BPC-157 come almost entirely from cell-culture and rodent work. Research suggests it may promote angiogenesis — the formation of new blood vessels — through upregulation of VEGFR2 signaling at sites of tissue injury. Animal studies also implicate modulation of the nitric oxide system in its reported vascular and cytoprotective effects, and increased expression of the early growth response factor Egr-1, which in turn is associated with FGF- and PDGF-type growth-factor cascades and fibroblast activity. Across preclinical models, investigators have described accelerated healing in tendon, ligament, muscle, bone, and gastrointestinal tissue, along with protective effects in ulcer and inflammatory-bowel models. These are hypotheses generated in animals, not demonstrated outcomes in people.
It is important to state the evidence quality plainly: as of this writing there are essentially no completed, controlled human efficacy trials of BPC-157, and results observed in animals frequently fail to translate to humans. The compound is not approved for human use by any regulatory authority and is prohibited by WADA at all times. BPC-157 is offered here strictly for research and educational purposes only and is not intended for human consumption.
Molecular data
Mechanism of action
In preclinical research, BPC-157 is associated with the following pathways and targets:
Research highlights
- Promotes VEGFR2-mediated angiogenesis in preclinical wound models
- Stimulates fibroblast migration and tendon outgrowth in ex vivo studies
- Upregulates Egr-1, driving PDGF and FGF growth factor cascade
- Active across tendon, ligament, muscle, bone, and GI tissue models
Frequently asked questions
What does BPC-157 do in research models?
In preclinical cell and animal studies, BPC-157 has been associated with promoting new blood-vessel formation (angiogenesis) and activating growth-factor signaling at sites of tissue injury. Researchers have reported accelerated healing responses across tendon, ligament, muscle, bone, and gastrointestinal tissue models. These are observations in laboratory settings and have not been confirmed as effects in humans.
Is BPC-157 approved for human use?
No. BPC-157 is not approved for human use by any global regulatory authority, and U.S. regulators have flagged it in consumer products as an unapproved drug. It is also prohibited by WADA at all times under its unapproved-substances category. It is sold strictly for laboratory research and educational purposes.
Are there human clinical trials on BPC-157?
There are essentially no completed, controlled human efficacy trials of BPC-157. The published evidence base is almost entirely preclinical — cell cultures and animal models — and findings in animals often do not translate to people. Any claim about human outcomes should be treated as an untested hypothesis.
What is the proposed mechanism of BPC-157?
Preclinical research suggests several possible mechanisms, including upregulation of VEGFR2-mediated angiogenesis, modulation of the nitric oxide pathway, and increased Egr-1 expression driving FGF/PDGF-type growth-factor signaling and fibroblast activity. These mechanisms are proposed from laboratory work and remain unproven in humans.
How is BPC-157 related to the Wolverine blend?
BPC-157 is one of the two peptides in the Wolverine blend, where it is combined with TB-500. The rationale researchers cite is that BPC-157's angiogenic signaling and TB-500's actin-regulating activity target complementary pathways in tissue-repair models. This pairing is studied preclinically and is not established for human use.
Source BPC-157 at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop BPC-157 at Purgo Labs ↗Related compounds
For research and educational purposes only. BPC-157 is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.